1. Multicentre randomized controlled trial with sensor-augmented pump vs multiple daily injections in hospitalized patients with type 2 diabetes in China: Time to reach target glucose
   W. Gu et al, 2017, Diabetes & Metabolism CrossRef
2. Research on the influence of fear appeals on APP users' privacy protection behavior
   Xingzhen Zhu et al, 2018, Proceedings of the 2018 International Conference on Information Management & Management Science - IMMS '18 CrossRef
3. Comparative assessment of immunogenicity of recombinant insulin Aspart from BioGenomics and its originator NovoRapid® in adult patients with type 2 diabetes mellitus
   A. Mishra et al, 2023, Journal of Endocrinological Investigation CrossRef
4. Efficacy, safety, and immunogenicity of recombinant insulin aspart (BioGenomics Limited) and NovoRapid® (Novo Nordisk) in adults with type 2 diabetes mellitus: a randomized, open-label, multicenter, phase-3 study
   Sneha A. Dongre et al, 2024, Research in Pharmaceutical Sciences CrossRef